Literature DB >> 34264814

Practice-changing publications in functional urology: A case-based approach.

Laura N Nguyen1, Ashley Cox2.   

Abstract

Year:  2021        PMID： 34264814      PMCID： PMC8279239          DOI： 10.5489/cuaj.7468

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  16 in total

Review 1.  Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy.

Authors:  Katie K Crean-Tate; Stephanie S Faubion; Holly J Pederson; Jennifer A Vencill; Pelin Batur
Journal:  Am J Obstet Gynecol       Date:  2019-08-29       Impact factor: 8.661

2.  CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome.

Authors:  Ashley Cox; Nicole Golda; Genevieve Nadeau; J Curtis Nickel; Lesley Carr; Jacques Corcos; Joel Teichman
Journal:  Can Urol Assoc J       Date:  2016-05-12       Impact factor: 1.862

3.  Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).

Authors:  Adrian Wagg; David Staskin; Eli Engel; Sender Herschorn; Rita M Kristy; Carol R Schermer
Journal:  Eur Urol       Date:  2019-11-13       Impact factor: 20.096

4.  International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.

Authors:  David Staskin; Jeffrey Frankel; Susann Varano; Denise Shortino; Rachael Jankowich; Paul N Mudd
Journal:  J Urol       Date:  2020-02-18       Impact factor: 7.450

5.  Hunner Lesion Phenotype in Interstitial Cystitis/Bladder Pain Syndrome: A Systematic Review and Meta-Analysis.

Authors:  H Henry Lai; Nicholas A Pickersgill; Joel M Vetter
Journal:  J Urol       Date:  2020-03-30       Impact factor: 7.450

6.  Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).

Authors:  Hidehiro Kakizaki; Kyu-Sung Lee; Osamu Yamamoto; Jar Jar Jong; Daisuke Katou; Budiwan Sumarsono; Satoshi Uno; Osamu Yamaguchi
Journal:  Eur Urol Focus       Date:  2019-11-11

7.  Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

Authors:  Henry D Mitcheson; Suvajit Samanta; Karen Muldowney; Cathy A Pinto; Beatriz de A Rocha; Stuart Green; Nathan Bennett; Paul N Mudd; Tara L Frenkl
Journal:  Eur Urol       Date:  2018-10-25       Impact factor: 20.096

8.  Fosfomycin Trometamol versus Comparator Antibiotics for the Treatment of Acute Uncomplicated Urinary Tract Infections in Women: A Systematic Review and Meta-Analysis.

Authors:  Tommaso Cai; Irene Tamanini; Carlo Tascini; Bela Köves; Gernot Bonkat; Mauro Gacci; Andrea Novelli; Juan Pablo Horcajada; Truls E Bjerklund Johansen; George Zanel
Journal:  J Urol       Date:  2019-10-25       Impact factor: 7.450

9.  Mirabegron Vs Placebo Add-on Therapy in Men With Overactive Bladder Symptoms Receiving Tamsulosin for Underlying Benign Prostatic Hyperplasia: A Safety Analysis From the Randomized, Phase 4 PLUS Study.

Authors:  Sender Herschorn; Kevin T McVary; Javier Cambronero Santos; Steve Foley; Rita M Kristy; Nurul Choudhury; John Hairston; Steven A Kaplan
Journal:  Urology       Date:  2020-10-10       Impact factor: 2.649

10.  Increased risk of incident dementia following use of anticholinergic agents: A systematic literature review and meta-analysis.

Authors:  Roger R Dmochowski; Sydney Thai; Kristy Iglay; Ekene Enemchukwu; Silvia Tee; Susann Varano; Cynthia Girman; Larry Radican; Paul N Mudd; Charles Poole
Journal:  Neurourol Urodyn       Date:  2020-10-23       Impact factor: 2.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.